Search research articles
Contact Us
Filters
Showing results (1-10 of 157) with videos related to
Page
of 16
Sort By:
Oncoimmunology
|
December 18, 2012
Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
Taku Fujimura, Yumi Kambayashi, Setsuya Aiba
Acta Dermato-Venereologica
|
April 11, 2013
Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma
Yumi Kambayashi, Taku Fujimura, Setsuya Aiba
Case Reports in Dermatology
|
April 30, 2013
Profiles of cytotoxic T lymphocytes in cutaneous lymphoid hyperplasia of the face
Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, et al.
Frontiers in Oncology
|
December 16, 2021
Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, et al.
Frontiers in Medicine
|
August 17, 2019
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
Yumi Kambayashi, Taku Fujimura, Takanori Hidaka, et al.
Pharmaceutics
|
February 5, 2021
Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
Taku Fujimura, Ryo Amagai, Yumi Kambayashi, et al.
The Journal of Dermatology
|
October 1, 2024
Segmental lichen aureus: A case report of zosteriform distribution and severe pain with literature review
Jun Yamamoto, Yumi Kambayashi, Shigeru Kuroki, et al.
Case Reports in Dermatology
|
December 22, 2011
Therapy-resistant, spontaneously remitting generalized neutrophilic eccrine hidradenitis in a healthy patient decreases the expression of dermcidin in affected eccrine glands
Yumi Kambayashi, Taku Fujimura, Kenshi Yamasaki, et al.
Case Reports in Dermatology
|
June 29, 2012
Basal cell carcinoma with spontaneous regression: a case report and immunohistochemical study
Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, et al.
Expert Opinion on Investigational Drugs
|
December 18, 2018
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
Taku Fujimura, Takanori Hidaka, Yumi Kambayashi, et al.
Page
of 16
Search research articles
Search
Showing results (1-10 of 157) with videos related to
Sort By:
Page
of 16
Oncoimmunology
|
December 18, 2012
Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
Taku Fujimura, Yumi Kambayashi, Setsuya Aiba
Acta Dermato-Venereologica
|
April 11, 2013
Comparison of immunosuppressive and immunomodulatory cells in keratoacanthoma and cutaneous squamous cell carcinoma
Yumi Kambayashi, Taku Fujimura, Setsuya Aiba
Case Reports in Dermatology
|
April 30, 2013
Profiles of cytotoxic T lymphocytes in cutaneous lymphoid hyperplasia of the face
Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, et al.
Frontiers in Oncology
|
December 16, 2021
Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, et al.
Frontiers in Medicine
|
August 17, 2019
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
Yumi Kambayashi, Taku Fujimura, Takanori Hidaka, et al.
Pharmaceutics
|
February 5, 2021
Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas
Taku Fujimura, Ryo Amagai, Yumi Kambayashi, et al.
The Journal of Dermatology
|
October 1, 2024
Segmental lichen aureus: A case report of zosteriform distribution and severe pain with literature review
Jun Yamamoto, Yumi Kambayashi, Shigeru Kuroki, et al.
Case Reports in Dermatology
|
December 22, 2011
Therapy-resistant, spontaneously remitting generalized neutrophilic eccrine hidradenitis in a healthy patient decreases the expression of dermcidin in affected eccrine glands
Yumi Kambayashi, Taku Fujimura, Kenshi Yamasaki, et al.
Case Reports in Dermatology
|
June 29, 2012
Basal cell carcinoma with spontaneous regression: a case report and immunohistochemical study
Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, et al.
Expert Opinion on Investigational Drugs
|
December 18, 2018
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
Taku Fujimura, Takanori Hidaka, Yumi Kambayashi, et al.
Page
of 16